ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2217-Kogarah-St-George-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
28
trial(s) found.
NCT06960577
Curative
Phase 3
Recruiting
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (
D933RC00002
)
anti-PD-L1 monoclonal antibody
Bladder cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NA
NA
NCT06943872
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
BGB-11417-303
)
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2480 - Lismore - Lismore Base Hospital
2500 - Wollongong - Wollongong Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6005 - West Perth - Perth Blood Institute
6168 - Cooloongup - Rockingham Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06634589
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06526793
Haem
Phase 2
Recruiting
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (
SOUNDTRACK-B
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06417814
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (
TROPION-Lung15
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06350097
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (
TROPION-Lung14
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
ABBV-383
Bortezomib
Carfilzomib
Dexamethasone
Elotuzumab
Pomalidomide
Selinexor
XPO1 inhibitor
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cancer therapy,CS1-targeting
cancer therapy,XPO1-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,BCMA-targeting
immuno-oncology therapy,CS1-targeting
immunomodulatory imide drug
proteasome inhibitor
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06074588
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (
2870-004
)
anti-Trop2 antibody-drug conjugate
antimetabolite
taxane
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
NCT06064877
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (
FIERCE-HN
)
anti-EGFR monoclonal antibody
anti-HGF monoclonal antibody
placebo
Head and neck squamous cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2217 - Kogarah - St George Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05647122
Advanced
Phase 1
Recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors (
EGRET
)
anti EGFR/cMET antibody-drug conjugate
Head and neck squamous cell carcinoma
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05555732
Advanced
Phase 3
Recruiting
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (
DS1062-A-U303
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (TERMINATED)
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05382299
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (
ASCENT-03
)
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NSW
2217 - Kogarah - St George Hospital
2060 - North Sydney - Mater Hospital (WITHDRAWN)
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
2640 - Albury - Border Medical Oncology Research Unit (WITHDRAWN)
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart (WITHDRAWN)
NCT05259839
Haem
Phase 1
Recruiting
A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma (
M22-947
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05150457
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (
BNA035-101
)
bispecific EGFR/4-1BB antibody
Solid tumour
NSW
2217 - Kogarah - St George Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
NCT04973137
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care Vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis (
AFFIRM-AL
)
anti-amyloid monoclonal antibody
placebo
Solid tumour
NSW
2217 - Kogarah - St George Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (WITHDRAWN)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04623541
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Small lymphocytic lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04170283
Haem
Phase 3
Enrolling by invitation
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (
BGB-3111-LTE1
)
BTK inhibitor
B-cell malignancy
NOT Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2606 - Canberra - Paratus Clinical Research Woden
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03229200
Haem
Phase 4
Enrolling by invitation
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. (
PCYC-1145-LT
)
BTK inhibitor
Leukaemia
Lymphoma
Solid tumour
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NCT02966756
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (
M14-728
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624001230549
Curative
Phase 2 / Phase 3
Not yet recruiting
An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.
Irinotecan
Mitomycin
Oxaliplatin
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6027 - Joondalup - Joondalup Health Campus
ACTRN12623001333606
Curative
Phase 2
Not yet recruiting
The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs) (
CCaLM
)
anti-CEACAM5 monoclonal antibody
Colon adenocarcinoma
NSW
2217 - Kogarah - St George Hospital
ACTRN12621001537842
Advanced
Phase 1 / Phase 2
Recruiting
Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1). (
NOX66-IS-002--CA209-66P,
)
anti-PD-1 monoclonal antibody
idronoxil suppository
Solid tumour
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2217 - Kogarah - St George Hospital
2228 - Miranda - Southside Cancer Care Centre
ACTRN12621001410842
Radonc
Not Applicable
Recruiting
Phase II Clinical Trial of the Feasibility of Hyper-Accelerated Partial Breast Radiotherapy in Women with Invasive Non-Lobular Breast Carcinoma (
HEARTBEAT
)
radiotherapy
Breast cancer
NSW
2217 - Kogarah - St George Hospital
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
NCT02643511
Radonc
Phase 2
Unknown
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer (
STGAF
)
Prostate cancer
NSW
2217 - Kogarah - St George Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (22)
Not yet recruiting (3)
Enrolling by invitation (2)
Unknown (1)
Recruitment Country and State
NSW (28)
VIC (22)
QLD (16)
WA (14)
SA (11)
NZ (6)
ACT (1)
TAS (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (12)
Phase 4 (2)
Trial Type
Haem (13)
Advanced (10)
Curative (3)
Radonc (2)
Cancer Therapy Class
Bcl2
18%
EGFR
18%
Trop2
18%
PD-1/PD-L1
14%
BTK
14%
CD20
11%
cereblon
11%
PD-1
11%
BCMA
7%
DNA methyltransferase
7%
PD-L1
4%
CD19
4%
JAK1
4%
JAK2
4%
MDM2
4%
CS1
4%
XPO1
4%
proteasome
4%
HGF
4%
VEGF
4%
AR
4%
CYP17A1
4%
androgen axis
4%
CD38
4%
4-1BB
4%
amyloid
4%
CEACAM5
4%
Facility
2217 - Kogarah - St George Hospital (28)
3168 - Clayton - Monash Medical Centre (12)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
4102 - Woolloongabba - Princess Alexandra Hospital (9)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
3004 - Melbourne, Southbank - Alfred Health (6)
NZ.0622 - Takapuna - North Shore Hospital (6)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (6)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
6150 - Murdoch - Fiona Stanley Hospital (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
5042 - Bedford Park - Flinders Medical Centre (4)
2139 - Concord - Concord Repatriation General Hospital (4)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
2170 - Liverpool - Liverpool Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
2500 - Wollongong - Wollongong Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
4032 - Chermside - The Prince Charles Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
NA
2480 - Lismore - Lismore Base Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
6168 - Cooloongup - Rockingham Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2060 - North Sydney - Mater Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4215 - Southport - Gold Coast University Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2606 - Canberra - Paratus Clinical Research Woden (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2025 - Papatoetoe - Middlemore Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
2228 - Miranda - Southside Cancer Care Centre (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
B-cell malignancy
Leukaemia
Lymphoma
B-cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Myeloproliferative neoplasm
Multiple myeloma
Plasma cell disorder
Head and neck cancer
Head and neck squamous cell carcinoma
Male genital cancers
Prostate cancer
Breast cancer
Acute myeloid leukaemia
Myeloid leukaemia
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Bladder cancer
Follicular lymphoma
Myelofibrosis
Non-squamous non-small-cell lung cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Breast adenocarcinoma
Triple-negative breast cancer
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Colon adenocarcinoma
Colorectal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy